Injection, delandistrogene moxeparvovec-rokl, per therapeutic dose
Code effective Jan 01, 2024
HCPCS Section
Drugs administered other than oral method, chemotherapy drugs
J1413 is a valid 2026 HCPCS code meaning Injection, delandistrogene moxeparvovec-rokl, per therapeutic dose or (Inj delandistrogene mox rokl) for short. HCPCS J1413 has been effective since 01/01/2024 and applies to Medical care.
|
HCPCS Level II Code Section J - Drugs administered other than oral method, chemotherapy drugs |
|
| HCPCS Code | J1413 |
|---|---|
| Description |
Long description:
Short description: |
| HCPCS Pricing indicator |
51 - Drugs
|
| Multiple pricing indicator |
A - Not applicable as HCPCS priced under one methodology
|
| Coverage code | C - Carrier judgment |
| ASC payment group code | Effective Jan 01, 2024 - This procedure is approved to be performed in an ambulatory surgical center. |
| BETOS2 code | O1E - Other drugs |
| HCPCS Action code | N - No maintenance for this code |
| Type of service | 1 - Medical care |
| Effective date | Effective Jan 01, 2024 |
| Date added | Added Jan 01, 2024 |
1 Two-digit numeric codes are Level I code modifiers copyrighted© by the American Medical Association's Current Procedural Terminology (CPT).
2 BETOS stands for “Berenson-Eggers Type Of Service”
HCPCS Level II codes and descriptors are approved and maintained jointly by the alpha-numeric editorial panel (consisting of CMS, the Health Insurance Association of America, and the Blue Cross and Blue Shield Association). — Updated 6/23/2026
CPT® is a registered trademark of the American Medical Association (AMA). All rights reserved.